Download PDF
Aktuelle Ernährungsmedizin 2012; 37(05): 287-306
DOI: 10.1055/s-0032-1305309
CME-Weiterbildung
© Georg Thieme Verlag KG Stuttgart · New York

Pro- und Präbiotika

Probiotics and Prebiotics
S. C. Bischoff
Institut für Ernährungsmedizin, Universität Hohenheim, Stuttgart
,
K. Köchling
Institut für Ernährungsmedizin, Universität Hohenheim, Stuttgart
› Author Affiliations
Further Information

Publication History

Publication Date:
08 October 2012 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Darmmikrobiota ist von großer Bedeutung für die Gesundheit und spielt bei zahlreichen Erkrankungen eine Rolle. Aufgrund dieser Tatsache sind die potenziellen Einsatzmöglichkeiten von Pro- und Präbiotika für Prävention und Therapie von Erkrankungen in den vergangenen Jahren zunehmend ins Interesse der Wissenschaft gerückt. Zahlreiche probiotische und – in geringerem Umfang – auch präbiotische Lebensmittel, Nahrungsergänzungsmittel und Arzneimittel sind heute erhältlich. Probiotika sind lebende Mikroorganismen, die dem Wirt einen gesundheitlichen Nutzen bringen können. Dabei handelt es sich vielfach um Stämme der Gattungen Laktobazillen und Bifidobakterien. Inzwischen gilt die Wirkung von Probiotika bei der Therapie akuter infektiöser Diarrhö, dem Reizdarmsyndrom, der Remissionserhaltung bei Colitis ulcerosa und Pouchitis sowie bei der Prävention von antibiotikaassoziierter Diarrhö und nekrotisierender Enterokolitis als gesichert. Bei einigen anderen Erkrankungen gibt es gewisse Hinweise auf einen Effekt von Probiotika, die sich jedoch in weiteren wissenschaftlichen Studien bestätigen müssen. Im primärpräventiven Bereich sind probiotische Wirkungen weniger klar belegt. Zur Erzielung einer Wirkung sind beim Einsatz von Probiotika mehrere Faktoren zu berücksichtigen, allen voran ihre Stammspezifität. Präbiotika sind selektiv fermentierte Substanzen wie Inulin und Oligofruktose, die bestimmte Spezies der gastrointestinalen Mikrobiota und so die Gesundheit des Wirts fördern können. Die Wirkmechanismen und -bereiche sind weniger gut untersucht als die der Probiotika.

Abstract

The intestinal microbiota is of relevant importance for health and plays a role in numerous diseases. Due to this, the potential application fields of pro- and prebiotics for prevention and therapy of diseases are more and more propelled into the focus of scientific research during the last years. Numerous probiotic, and in a smaller scale also prebiotic, food, nutritional supplements, and pharmaceuticals are available today. Probiotics are living microorganisms, which can improve the health of the host. The most frequent probiotic microorganisms are strains of lactobacilli and bifidobacteria. Today, the effects of probiotics in the therapy of acute infectious diarrhea, irritable bowel syndrome, maintenance of remission of pouchitis and ulcerative colitis as well as the prevention of antibiotic associated diarrhea and necrotizing enterocolitis are regarded as evidenced. For some other diseases there is more or less strong evidence for an effect of probiotics, which has to be proven in further scientific studies. There are some factors that have to be considered when using probiotics, especially the strain specifity. Prebiotics are selectively fermented substances like inulin or oligofructose that beneficially affect the gastrointestinal microbiota and with this the host health. The mechanisms and fields of application are less good investigated than those of probiotics.

Schlüsselwörter

Probiotika - Präbiotika - Darmmikrobiota - darmassoziiertes Immunsystem

Keywords

probiotics - prebiotics - intestinal microbiota - gut associated immune system
 

  • Literatur

  • 1 Frei R, Lauener RP, Crameri R et al. Microbiota and dietary interactions – an update to the hygiene hypothesis?. Allergy 2012; 67: 451-461
    CrossrefPubMedGoogle Scholar
  • 2 FAO/WHO Expert Consultation. Guidelines for the Evaluation of Probiotics in Food. FAO/WHO; 2002
    Google Scholar
  • 3 ISAPP. 6th Meeting of the International Scientific Association of Probiotics and Prebiotics. London, Ontario: 2008
    PubMedGoogle Scholar
  • 4 Gibson HR, Probert HM, Loo JV et al. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutrition Research Reviews 2004; 17: 259-275
    CrossrefPubMedGoogle Scholar
  • 5 Roberfroid M, Gibson GR, Hoyles L et al. Prebiotic effects: metabolic and health benefits. Br J Nutr 2010; 104: S1-S63
    Google Scholar
  • 6 Savage DC. Microbial Ecology of the Gastrointestinal Tract. Ann Rev Microbiol 1977; 31: 107-133
    CrossrefPubMedGoogle Scholar
  • 7 Arumugam M, Raes J, Pelletier E et al. Enterotypes of the human gut microbiome. Nature 2011; 473: 74-180
    CrossrefPubMedGoogle Scholar
  • 8 Qin J, Li R, Raes J et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-67
    CrossrefPubMedGoogle Scholar
  • 9 Gill HS, Guarner F. Probiotics and human health: a clinical perspective. Postgrad Med J 2004; 80: 516-526
    CrossrefPubMedGoogle Scholar
  • 10 Blaut M, Clavel T. Metabolic Diversity of the Intestinal Microbiota: Implications for Health and Disease. J Nutr 2007; 137: 751S-755S
    PubMedGoogle Scholar
  • 11 Bischoff SC. “Gut health”: a new objective in medicine?. BMC Medicine 2011; 9: 24
    CrossrefPubMedGoogle Scholar
  • 12 Palmer C, Bik EM, DiGiulio DB et al. Development of the Human Infant Intestinal Microbiota. PLoS Biol 2007; 5: e177
    CrossrefPubMedGoogle Scholar
  • 13 Thomas LV, Ockhuizen T. New insights into the impact of the intestinal microbiota on health and disease: a symposium report. Br J Nutr 2012; 107: S1-S13
    CrossrefPubMedGoogle Scholar
  • 14 Enck P, Zimmermann K, Rusch K et al. The effects of Ageing on the Colonic Bacterial Microflora in Adults. Z Gastroenterol 2009; 47: 653-658
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Falk PG, Hooper LV, Midtvedt T et al. Creating and maintaining the gastrointestinal ecosystem: what we know and need to know from gnotobiology. Microbiol Mol Biol Rev 1998; 62: 1157-1170
    PubMedGoogle Scholar
  • 16 Garn H, Renz H. Epidemiological and immunological evidence for the hygiene hypothesis. Immunobiology 2007; 212: 441-452
    CrossrefPubMedGoogle Scholar
  • 17 Schaub B, Lauener R, von Mutius E. The many faces of the hygiene hypothesis. J Allergy Clin Immunol 2006; 117: 969-977
    CrossrefPubMedGoogle Scholar
  • 18 Macfarlane GT, Steed H, Macfarlane S. Bacterial metabolism and health-related effects of galacto-oligosaccharides and other prebiotics. Journal of Applied Microbiology 2008; 104: 305-344
    PubMedGoogle Scholar
  • 19 Meier R. Die Abwehr unterstützen. Wie die intestinale Mikrobiota das adaptive und angeborene Immunsystem stimulieren kann. Aktuel Ernaehrungsmed 2012; 37 (Suppl. 01) S11-S14
    PubMedGoogle Scholar
  • 20 Ölschläger TA, Hacker J. Definition und Wirkmechanismen der Probiotika, Präbiotika und Synbiotika. In: Bischoff SC, Hrsg. Probiotika, Präbiotika und Synbiotika. 1.. Aufl. Stuttgart: Thieme; 2009
    Google Scholar
  • 21 Rowland I, Capurso L, Collins K et al. Current level of consensus on probiotic science. Gut Microbes 2010; 1: 436-439
    CrossrefPubMedGoogle Scholar
  • 22 de Vrese M, Schrezenmeir J. Präventive Bedeutung von probiotischen Joghurts. In: Bischoff SC, Hrsg. Probiotika, Präbiotika und Synbiotika. 1.. Aufl. Stuttgart: Thieme; 2009
    Google Scholar
  • 23 Jacobson CN, Rosenfeldt Nielsen V, Hayford AE et al. Screening of Probiotic Activities of Forty-Seven Strains of Lactobacillus spp. by In Vitro Techniques and Evaluation of the Colonization Ability of Five Selected Strains in Humans. Appl Environ Microbiol 1999; 65: 4949-4956
    PubMedGoogle Scholar
  • 24 BgVV Arbeitsgruppe „Probiotische Mikroorganismen in Lebensmitteln“. Abschlussbericht (1999). Im Internet: http://www.bfr.bund.de/cm/343/probiot.pdf Stand: 07.05.2012
    PubMedGoogle Scholar
  • 25 Asemi Z, Jazayeri S et al. Effects of daily consumption of probiotic yoghurt on inflammatory factors in pregnant women: a randomized controlled trial. Pak J Biol Sci 2011; 14: 476-482
    CrossrefPubMedGoogle Scholar
  • 26 de Vrese M, Kristen H, Rautenberg P et al. Probiotic lactobacilli and bifidobacteria in a fermented milk product with added fruit preparation reduce antibiotic associated diarrhea and Helicobacter pylori activity. J Dairy Res 2011; 78: 396-403
    CrossrefPubMedGoogle Scholar
  • 27 Hickson M, D’Souza AL, Muthu N et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007; 335: 80
    CrossrefPubMedGoogle Scholar
  • 28 Sanders ME, Marco ML. Food formats for effective delivery of probiotics. Annu Rev Food Sci Technol 2010; 1: 65-85
    CrossrefPubMedGoogle Scholar
  • 29 Guarner F, Perdigon G, Corthier G et al. Should yoghurt cultures be considered probiotic?. Br J Nutr 2005; 93: 783-786
    CrossrefPubMedGoogle Scholar
  • 30 Heller KJ. „Pharmakokinetik“ und Sicherheit von Probiotika. In: Bischoff SC, Hrsg. Probiotika, Präbiotika und Synbiotika. 1.. Aufl. Stuttgart: Thieme; 2009
    Google Scholar
  • 31 Besselink MG, van Santvoort HC, Buskens E et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371 (9613) 651-659
    CrossrefPubMedGoogle Scholar
  • 32 Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr 2004; 38: 457-458
    CrossrefPubMedGoogle Scholar
  • 33 Bischoff SC, Zeitz M. Scientific evidence for the medical use of probiotics. Ann Nutr Metab 2010; 57: 1-5
    PubMedGoogle Scholar
  • 34 Szajewska H. Advances and Limitations of Evidence-Based Medicine – Impact for Probiotics. Ann Nutr Metab 2010; 57 (Suppl. 01) 6-9
    CrossrefPubMedGoogle Scholar
  • 35 McFarland LV. Probiotics and Diarrhea. Ann Nutr Metab 2010; 57 (Suppl. 01) 10-11
    CrossrefPubMedGoogle Scholar
  • 36 Guandalini S. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol 2011; 45 (Suppl. 01) 49-53
    PubMedGoogle Scholar
  • 37 Guandalini S. Probiotics for children with diarrhea: an update. J Clin Gastroenterol 2008; 42 (Suppl. 02) 53-57
    CrossrefPubMedGoogle Scholar
  • 38 Guarino A, Albano F, Ashkenazi S et al. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases. Evidence-based guidelines for the management of acute gastroenteritis in children in Europe: executive summary. J Pediatr Gastroenterol Nutr 2008; 46: 619-621
    PubMedGoogle Scholar
  • 39 D'Souza AL, Rajkumar C, Cooke J et al. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002; 324: 1361
    CrossrefPubMedGoogle Scholar
  • 40 Parkes GC, Sanderson JD, Whelan K. The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhea. Lancet Infect Dis 2009; 9: 237-244
    CrossrefPubMedGoogle Scholar
  • 41 Johnston BC, Goldenberg JZ, Vandvik PO et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2011; 11 CD004827
    PubMedGoogle Scholar
  • 42 de Souza DNP, Jorge MT. The effect of Lactobacillus casei and Bifidobacterium breve on antibioticassociated diarrhea treatment: randomized double-blind clinical trial. Rev Soc Bras Med Trop 2012; 45: 112-116
    CrossrefPubMedGoogle Scholar
  • 43 Kassinen A, Krogius-Kurrika L, Mäkivuokko H et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24-33
    CrossrefPubMedGoogle Scholar
  • 44 Meier R. Probiotics in Irritable Bowel Syndrome. Ann Nutr Metab 2010; 57 (Suppl. 01) 12-13
    CrossrefPubMedGoogle Scholar
  • 45 Layer P, Andresen V, Pehl C et al. S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM). Z Gastroenterol 2011; 49: 237-293
    Google Scholar
  • 46 Moayyedi P, Ford AC, Talley NJ et al. The efficiacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut 2008; 59: 325-532
    PubMedGoogle Scholar
  • 47 Girardin M, Seidman E. Indications for the Use of Probiotics in Gastrointestinal Diseases. Dig Dis 2011; 29: 574-587
    CrossrefPubMedGoogle Scholar
  • 48 McKenzie YA, Alder A, Anderson W et al. British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults. J Hum Nutr Diet 2012; doi: DOI: 10.1111/j.1365-277X.2012.01242.x.
    PubMedGoogle Scholar
  • 49 Kruis W, Fric P, Prokrotnieks J et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623
    CrossrefPubMedGoogle Scholar
  • 50 Henker J, Müller S, Laass MW et al. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Z Gastroenterol 2008; 46: 874-875
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Dignass A, Preiß JC, Aust DE et al. AWMF online. Aktualisierte S3-Leitlinie zur Diagnostik und Therapie der Colitis ulcerosa. Ergebnisse einer evidenzbasierte Konsensuskonferenz (2011). Im Internet: http://www.awmf.org/uploads/tx_szleitlinien/021-009l_S3_Colitis_ulcerosa_Diagnostik_Therapie_2011.pdf Stand: 31.05.2012
    Google Scholar
  • 52 Pardi DS, D’Haens G, Shen B et al. Clinical Guidelines for the Management of Pouchitis. Inflamm Bowel Dis 2009; 15: 1424-1431
    CrossrefPubMedGoogle Scholar
  • 53 Gionchetti P, Rizzello F, Venturi A et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 305-309
    CrossrefPubMedGoogle Scholar
  • 54 Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS ONE 2012; 7: e34938
    CrossrefPubMedGoogle Scholar
  • 55 Gionchetti P, Rizzello F, Helwig U et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124: 1202-1209
    CrossrefPubMedGoogle Scholar
  • 56 Deshpande G, Rao S, Patole S. Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birthweight: a systematic review of randomised controlled trials. Lancet 2007; 369: 1614-1620
    CrossrefPubMedGoogle Scholar
  • 57 Alfaleh K, Anabrees J, Bassler D et al. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2011; 16 CD005496
    PubMedGoogle Scholar
  • 58 Mihatsch WA, Braegger CP, Decsic T et al. Critical systematic review of the level of evidence for routine use of probiotics for reduction of mortality and prevention of necrotizing enterocolitis and sepsis in preterm infants. Clin Nutr 2012; 31: 6-15
    CrossrefPubMedGoogle Scholar
  • 59 Förster-Holst R. Probiotics in the treatment and prevention of Atopic Dermatitis. Ann Nutr Metab 2010; 57 (Suppl. 01) 16-19
    CrossrefPubMedGoogle Scholar
  • 60 van der Aa LB, Heymans HSA, van Aalderen WMC et al. Probiotics and prebiotics in atopic dermatitis: review of the theoretical background and clinical evidence. Pediatr Allergy Immunol 2010; 21: e355-e367
    CrossrefPubMedGoogle Scholar
  • 61 Kalliomäki M, Salminen S, Arvilommi H et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001; 357: 1076-1079
    CrossrefPubMedGoogle Scholar
  • 62 Kalliomäki M, Salminen S, Poussa T et al. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003; 361: 1869-1871
    CrossrefPubMedGoogle Scholar
  • 63 Kopp MV, Hennemuth I, Heinzmann A et al. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation. Pediatrics 2008; 121: e850-856
    CrossrefPubMedGoogle Scholar
  • 64 Grüber C, Wendt M, Sulser C et al. Randomized, placebo-controlled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancy. Allergy 2007; 62: 1270-1276
    CrossrefPubMedGoogle Scholar
  • 65 Brouwer ML, Wolt-Plompen SA, Dubois AE et al. No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. Clin Exp Allergy 2006; 36: 899-906
    CrossrefPubMedGoogle Scholar
  • 66 Pelucchi C, Chatenoud L, Turati F et al. Probiotics Supplementation During Pregnancy or Infancy for the Prevention of Atopic Dermatitis: A Meta-analysis. Epidemiology 2012; 23: 402-414
    CrossrefPubMedGoogle Scholar
  • 67 Meuer S. Probiotics and Respiratory Tract Diseases. Ann Nutr Metab 2010; 57 (Suppl. 01) 24-26
    CrossrefPubMedGoogle Scholar
  • 68 Guillemard E, Tanguy J, Flavigny A et al. Effects of consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN 114001 on common respiratory and gastrointestinal infections in shift workers in a randomized controlled trial. J Am Coll Nutr 2010; 29: 455-468
    CrossrefPubMedGoogle Scholar
  • 69 Guillemard E, Tondu F, Lacoin F et al. Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial. Br J Nutr 2010; 103: 58-68
    CrossrefPubMedGoogle Scholar
  • 70 Maldonado J, Cañabate F, Sempere L et al. Human milk probiotic Lactobacillus fermentum CECT5716 reduces the incidence of gastrointestinal and upper respiratory tract infections in infants. J Pediatr Gastroenterol Nutr 2012; 54: 55-61
    CrossrefPubMedGoogle Scholar
  • 71 Hojsak I, Abdović S, Szajewska H et al. Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections. Pediatrics 2010; 125: e1171-1177
    CrossrefPubMedGoogle Scholar
  • 72 Leyer GJ, Li S, Mubasher ME et al. Probiotic effects on cold and influenza-like symptom incidence and duration in children. Pediatrics 2009; 124: e172-179
    CrossrefPubMedGoogle Scholar
  • 73 Merenstein D, Murphy M, Fokar A et al. Use of a fermented dairy probiotic drink containing Lactobacillus casei (DN-114 001) to decrease the rate of illness in kids: the DRINK study. A patient-oriented, double-blind, cluster-randomized, placebo-controlled, clinical trial. Eur J Clin Nutr 2010; 64: 669-677
    CrossrefPubMedGoogle Scholar
  • 74 Gleeson M, Bishop NC, Oliveira M et al. Daily probiotic’s (Lactobacillus casei Shirota) reduction of infection incidence in athletes. Int J Sport Nutr Exerc Metab 2011; 21: 55-64
    PubMedGoogle Scholar
  • 75 Hao Q, Lu Z, Dong BR et al. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev 2011; 7 (9) CD006895
    PubMedGoogle Scholar
  • 76 Reid G, Dols J, Miller W. Targeting the vaginal microbiota with probiotics as a means to counteract infections. Curr Opin Clin Nutr Metab Care 2009; 12: 583-587
    CrossrefPubMedGoogle Scholar
  • 77 Rayes N, Soeters PB. Probiotics in Surgical and critically ill patients. Ann Nutr Metab 2010; 57 (Suppl. 01) 29-31
    CrossrefPubMedGoogle Scholar
  • 78 Lundell L. Use of Probiotics in Abdominal Surgery. Dig Dis 2011; 29: 570-573
    CrossrefPubMedGoogle Scholar
  • 79 Tong JL, Ran ZH, Shen J et al. Meta-analysis: The effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007; 25: 155-168
    PubMedGoogle Scholar
  • 80 Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of a Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32: 1069-1079
    CrossrefPubMedGoogle Scholar
  • 81 Deguchi R, Nakaminami H, Rimbara E et al. Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapie. J Gastroenterol Hepatol 2012; 27: 888-892
    CrossrefPubMedGoogle Scholar
  • 82 Matsushima M, Takagi A. “Is it effective?” to “How to use it?” The era has changed in probiotics and functional food products against Helicobacter pylori infection. J Gastroenterol Hepatol 2012; 27: 851-853
    CrossrefPubMedGoogle Scholar
  • 83 McFarland V. Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis 2007; 5: 97-105
    CrossrefPubMedGoogle Scholar
  • 84 Delzenne NM, Neyrinck AM, Bäckhed F et al. Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol 2011; 7: 639-646
    CrossrefPubMedGoogle Scholar
  • 85 Bischoff SC. Checkpoint für die Energiebalance – Zusammenhänge zwischen der Mikrobiota und dem Entstehen des metabolischen Syndroms sowie der Pathogenese der Adipositas. Aktuel Ernaehrungsmed 2012; 37 (Suppl. 01) 15-S18
    PubMedGoogle Scholar
  • 86 Levri KM, Ketvertis K, Deramo M et al. Do probiotics reduce adult lactose intolerance? A systematic review. J Fam Pract 2005; 54: 613-620
    PubMedGoogle Scholar
  • 87 Pool-Zobel BL, Neudecker C, Domizlaff I et al. Lactobacillus- and bifidobacterium-mediated antigenotoxicity in the colon of rats. Nutr Cancer 1996; 26: 365-380
    CrossrefPubMedGoogle Scholar
  • 88 Kumar M, Nagpal R, Kumar R et al. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res 2012; 2012: 902-917
    PubMedGoogle Scholar
  • 89 Burcelin R, Serino M, Chabo C et al. Gut microbiota and diabetes: from pathogenesis to therapeutic perspective. Acta Diabetol 2011; 48: 257-273
    CrossrefPubMedGoogle Scholar
  • 90 Teanpaisan R, Piwat S, Dahlén G. Inhibitory effect of oral Lactobacillus against oral pathogens. Lett Appl Microbiol 2011; 53: 452-459
    CrossrefPubMedGoogle Scholar
  • 91 Vivekananda MR, Vandana KL, Bhat KG. Effect of the probiotic Lactobacilli reuteri (Prodentis) in the management of periodontal disease: a preliminary randomized clinical trial. J Oral Microbiol 2010; 2: 5344
    PubMedGoogle Scholar
  • 92 Slawik S, Staufenbiel I, Schilke R et al. Probiotics affect the clinical inflammatory parameters of experimental gingivitis in humans. Eur J Clin Nutr 2011; 65: 857-863
    CrossrefPubMedGoogle Scholar
  • 93 Coudray C, Bellanger J, Castiglia-Delavaud C et al. Effect of soluble or partly soluble dietary fibres supplementation on absorption and balance of calcium, magnesium, iron and zinc in healthy young men. Eur J Clin Nutr 1997; 51: 375-380
    CrossrefPubMedGoogle Scholar
  • 94 Abrams SA, Hawthorne KM, Aliu O et al. An inulintype fructan enhances calcium absorption primarily via an effect on colonic absorption in humans. J Nutr 2007; 137: 2208-2212
    PubMedGoogle Scholar
  • 95 Tahiri M, Tressol JC, Arnaud J et al. Effect of shortchain fructooligosaccharides on intestinal calcium absorption and calcium status in postmenopausal women: a stable-isotope study. Am J Clin Nutr 2003; 77: 449-457
    PubMedGoogle Scholar
  • 96 Cashman KDA. A prebiotic substance persistently enhances intestinal calcium absorption and increases bone mineralization in young adolescents. Nutr Rev 2006; 64: 189-196
    CrossrefPubMedGoogle Scholar
  • 97 World Cancer Research Fund/American Institute for cancer research. Food, Nutrition, Physical Activity, and the Prevention of Cancer. A Global Perspective. Washington, DC: WCRF/AICR; 2007
    Google Scholar
  • 98 Femia AP, Luceri C, Dolara P et al. Antitumorigenic activity of the prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis on azoxymethane-induced colon carcinogenesis in rats. Carcinogenesis 2002; 23: 1953-1960
    CrossrefPubMedGoogle Scholar
  • 99 Rowland IR, Rumney CJ, Coutts JT et al. Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats. Carcinogenesis 1998; 19: 281-285
    CrossrefPubMedGoogle Scholar